# Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

> **NCT02218164** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Skin
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** Pegylated Interferon alpha-2b
- **DRUG:** Capecitabine
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT02218164
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-12
- **Primary completion:** 2017-07-19
- **Final completion:** 2018-06-25
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218164, "Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02218164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*